HUTCHMED (00013) rose more than 3% during intraday trading, with the stock up 2.42% as of press time, quoted at HK$23.72, with a turnover of HK$77.57499 million.
Citi released a research report stating that the bank held an expert meeting with the principal investigator of SANOVO on November 5, which further reinforced its positive view on the potential of savolitinib in first-line and post-osimertinib EGFR-mutant non-small cell lung cancer. The bank maintained its "Buy/High Risk" rating, listed HUTCHMED as its new top pick, and raised its target price from HK$40.1 to HK$43.2.
The bank believes that based on strong SAFFRON data, the new drug application for savolitinib has already been submitted in the United States and accepted in Japan and Europe. HUTCHMED's management expects potential overseas approval in the 2027 fiscal year. The bank is optimistic about the commercialization prospects and believes savolitinib could become a billion-dollar blockbuster drug, with further upside potential in the first-line opportunity.
The bank raised its revenue forecasts for fiscal years 2027/2028 by 4% and 2%, and increased its earnings per share estimates by 15% and 5%, mainly reflecting the potential overseas approval of savolitinib and adjustments to epidemiological models.
Comments